Autolus Therapeutics (AUTL) Gross Margin (2024 - 2026)
Autolus Therapeutics' (AUTL) quarterly Gross Margin came in at 4.29% in Q4 2025, up 3916123.0% YoY from N/an in Q4 2024, and up 87.81% on a QoQ basis from 35.15% in Q3 2025.
Autolus Therapeutics (AUTL) Gross Margin (2024 - 2026) Analysis & Trends
Autolus Therapeutics (AUTL) has 2 years of Gross Margin data on file, last reported at 4.29% in Q4 2025.
- Quarterly Gross Margin rose 3916123.0% year-over-year to 4.29% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 27.83% (down 1541.0% YoY) and the FY2025 annual result came in at 27.83%, down 1531.0% from the prior year.
- Gross Margin climbed to 4.29% in Q4 2025, from 35.15% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 100.0% in Q1 2024 to a low of 39165.52% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Autolus Therapeutics | 763.37 Mn | 561.74 Mn | 25.22 Mn | 55.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.20% |
| Dec 31, 2025 | -4.29% |
| Sep 30, 2025 | -35.15% |
| Jun 30, 2025 | -16.83% |
| Mar 31, 2025 | -99.86% |
| Dec 31, 2024 | -39,165.52% |
| Mar 31, 2024 | 100.00% |